Médecine

Paramédical

Autres domaines


S'abonner

The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study - 15/02/21

Doi : 10.1016/j.jaad.2020.08.035 
Tomasz Hawro, MD a, Katarzyna Przybyłowicz, MD a, Max Spindler, MD a, Marlena Hawro, PsyM a, Michał Steć, MSc b, Sabine Altrichter, MD a, Karsten Weller, MD a, Markus Magerl, MD a, Ulrich Reidel, MD a, Ezzat Alarbeed, MD a, Ola Alraboni, MD a, Marcus Maurer, MD a, , Martin Metz, MD a
a Department of Dermatology and Allergy, Charité–Universitätsmedizin Berlin, Berlin, Germany 
b Department of Computer Science, University of Potsdam, Potsdam, Germany 

Correspondence to: Marcus Maurer, MD, Department of Dermatology and Allergy, Charité–Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.Department of Dermatology and AllergyCharité–Universitätsmedizin BerlinCharitéplatz 1Berlin10117Germany

Abstract

Background

Pruritus often accompanies chronic skin diseases, exerting considerable burden on many areas of patient functioning; this burden and the features of pruritus remain insufficiently characterized.

Objective

To investigate characteristics, including localization patterns, and burden of pruritus in patients with chronic dermatoses.

Methods

We recruited 800 patients with active chronic skin diseases. We assessed pruritus intensity, localization, and further characteristics. We used validated questionnaires to assess quality of life, work productivity and activity impairment, anxiety, depression, and sleep quality.

Results

Nine out of every 10 patients had experienced pruritus throughout their disease and 73% in the last 7 days. Pruritus often affected the entire body and was not restricted to skin lesions. Patients with moderate to severe pruritus reported significantly more impairment to their sleep quality and work productivity, and they were more depressed and anxious than control individuals and patients with mild or no pruritus. Suicidal ideations were highly prevalent in patients with chronic pruritus (18.5%) and atopic dermatitis (11.8%).

Conclusions

Pruritus prevalence and intensity are very high across all dermatoses studied; intensity is linked to impairment in many areas of daily functioning. Effective treatment strategies are urgently required to treat pruritus and the underlying skin disease.

Le texte complet de cet article est disponible en PDF.

Key words : activity, anxiety, depression, pruritus, quality of life, sleep quality, suicidal ideations, work productivity

Abbreviations used : AD, CIndU, CP, CPG, CSU, CTCL, HADS, HR-QoL, IQR, QoL, VAS


Plan


 Funding sources: Supported in part by unrestricted grants from Novartis, Leo Pharma, and the Urticaria Network.
 Disclosure: Dr Hawro has received honoraria as a speaker and/or consultant from Moxie, Galderma, and Roche. Dr Altrichter has received honoraria as a speaker and/or consultant from Allakos, AstraZeneca, Novartis, Moxie, and CSL Behring. Dr Weller has received honoraria as a speaker and/or consultant from CSL Behring, Dr R. Pfleger, Novartis, Moxie, Shire/Takeda, UCB, Uriach, and Viropharma. Dr Magerl has received honoraria as a speaker and/or advisor and/or has received research funding from Biocryst, CSL Behring, Kalvista Pharmaceuticals, Novartis, Moxie, Pharming, and Shire/Takeda. Dr Maurer is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Alnylam, Aralez, AstraZeneca, Biocryst, Blueprint, CSL Behring, FAES, Genentech, Kalvista Pharmaceuticals, Menarini, Novartis, Leo Pharma, Moxie, Merck Sharp & Dohme, Pharming, Pharvaris, Roche, Sanofi, Shire/Takeda, UCB, and Uriach. Dr Metz has received honoraria as a speaker and/or consultant for Aralez Pharmaceuticals, argenx, Bayer, Beiersdorf, Celgene, Menlo, Moxie, Novartis, Roche, Sanofi, Sienna Biopharmaceuticals, and Uriach. Drs Przybyłowicz, Spindler, Hawro, Steć, Reidel, Alarbeed, and Alraboni have no conflicts of interest to declare.
 IRB approval status: The Ethics Committee of Charité - Universitätsmedizin Berlin approved the study (EA1/007/14).
 Reprints not available from the authors.


© 2020  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 84 - N° 3

P. 691-700 - mars 2021 Retour au numéro
Article précédent Article précédent
  • The risk of respiratory tract infections and interstitial lung disease with interleukin 12/23 and interleukin 23 antagonists in patients with autoimmune diseases: A systematic review and meta-analysis
  • Shintaro Akiyama, Akihiro Yamada, Dejan Micic, Atsushi Sakuraba
| Article suivant Article suivant
  • Modifiable lifestyle and environmental factors associated with onset of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational studies
  • Wenhui Xie, Hong Huang, Xuerong Deng, Dai Gao, Zhuoli Zhang

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.